其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Trifluperidol CAS Registry Number: 749-13-3 三氟哌利多

CAS Name: 1-(4-Fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1-butanone
Additional Names: 4'-fluoro-4-[4-hydroxy-4-(a,a,a-trifluoro-m-tolyl)piperidino]butyrophenone; p...
Literature References: Prepn: P. A. J. Janssen, GB 895309; idem, US 3438991 (1962, 1969 both to Janssen). Pharmacology: idem, Arzneim.-Forsch. 11, 932 (1961).

Droperidol CAS Registry Number: 548-73-2 氟哌利多

CAS Name: 1-[1-[4-(4-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-2H-benzimidazol-2-one
Additional Names: 1-[1-[3-(p-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]...
Literature References: Prepn: P. A. J. Janssen, J. F. Gardocki, US 3161645 (1964 to Janssen). Pharmacology and toxicity: J. Yelnosky et al., Toxicol. Appl. Pharmacol. 6, 37 (1964). Comprehensive description: C. A. Janicki, R. K. Gilpin, Anal. Profiles Drug Subs. 7, 171-192 (1978).

Cloxotestosterone CAS Registry Number: 53608-96-1 氯索睾酮

CAS Name: (17b)-17-(2,2,2-Trichloro-1-hydroxyethoxy)androst-4-en-3-one
Additional Names: testosterone 17-chloral hemiacetal
Percent Composition: C 57.87%, H 6.71%, Cl 24.40%, O 11.01%
Literature References: Prepn: P. Borrevang, US 2933514 (1960 to Lövens Kemiske Fabrik); idem, Acta Chem. Scand. 16, 883 (1962).

Metescufylline CAS Registry Number: 15518-82-8 甲七叶茶碱

CAS Name: [(7-Hydroxy-4-methyl-2-oxo-2H-1-benzopyran-6-yl)oxy]acetic acid compd with 7-[2-(diethylamino)ethyl]-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1)
Additional Names: 7-[2-(diethyl...
Literature References: Prepn: P. Chabrier et al., FR M1234 (1962 to Lab. Dausse), C.A. 57, 16769f (1962).

Efloxate CAS Registry Number: 119-41-5 乙酯黄酮

CAS Name: [(4-Oxo-2-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid ethyl ester
Additional Names: 7-flavone ethyl hydroxyacetate; ethyl flavon-7-yloxyacetate; ethyl 7-flavonoxyacetate; 7-flavonoxya...
Literature References: Prepn: P. Da Re et al., Farmaco Ed. Sci. 13, 561 (1958); GB 803372 and GB 824547 (1958, 1959 both to Recordati); P. Da Re, A. Colleoni, Ann. Chim. (Rome) 49, 1632 (1959).

Clidanac CAS Registry Number: 28968-07-2 6-氯-5-环己基-1-匚羧酸

CAS Name: 6-Chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid
Additional Names: (±)-6-chloro-5-cyclohexylindan-1-carboxylic acidTrademarks: Britai (BMS); Indanal (Takeda)
Perc...
Literature References: Prepn: P. F. Juby et al., DE 2004038; eidem, US 3565943 (1970, 1971 both to Bristol-Myers); S. Noguchi et al., Chem. Pharm. Bull. 19, 646 (1971). Synthesis and anti-inflammatory activity: eidem, ibid. 22, 529 (1974); G. R. Allen et al., J. Med. Chem. 15, 934 (1972); and toxicity data: P. F. Juby et al., ibid. 1297. Pharmacology: S. Kuzuna et al., Jpn. J. Antibiot. 24, 695 (1974), C.A. 82, 80297h (1976). X-ray crystallographic study: K. Kamiya et al., Chem. Pharm. Bull. 23, 1589 (1975). Metabolism: S. Tanayama, Y. Kanai, Xenobiotica 7, 145 (1977). Immunogenicity study: S. Kuzuna et al., Oyo Yakuri 19, 951 (1980), C.A. 94, 76682 (1981). Inhibition of prostaglandin biosynthesis: S. Tamura et al., J. Pharm. Pharmacol. 33, 29 (1981). Antipyretic effect in cancer patients: H. Furue, Curr. Ther. Res. 30, 71 (1981).

Febarbamate CAS Registry Number: 13246-02-1 非巴氨酯

CAS Name: 1-[2-[(Aminocarbonyl)oxy]-3-butoxypropyl]-5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
Additional Names: 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid carbamate; 1...
Literature References: Prepn: P. Gold-Aubert, E. Gysin, Helv. Chim. Acta 44, 105 (1961); P. Gold-Aubert, US 3075983 (1963 to Sapos). Pharmacology: E. Frommel et al., Helv. Physiol. Pharmacol. Acta 19, 241 (1961). Metabolism in rats: J. Vachta, P. Gold-Aubert, Eur. J. Drug Metab. Pharmacokinet. 7, 147 (1982); in man: J. Vachta et al., ibid. 8, 297 (1983).

Aceglutamide CAS Registry Number: 2490-97-3 N-乙酰-L-谷氨酰胺

CAS Name: N2-Acetyl-L-glutamine
Additional Names: a-N-acetyl-L-glutamine
Trademarks: Acutil-S (ISF)
Percent Composition: C 44.68%, H 6.43%, N 14.89%, O 34.01%
Literature References: Prepn: P. Karrer et al., Helv. Chim. Acta 9, 301 (1926); GB 792576 (1958 to Merck Co.), C.A. 53, 2109a (1959); I. J. Maschler, N. Lichtenstein, Biochim. Biophys. Acta 57, 252 (1962). Stability study: G. Sekules, G. Guadagnini, Farmaco Ed. Prat. 21, 22 (1966). NMR study: W. Voelter et al., Z. Naturforsch. 26B, 213 (1971). Fermentation study: T. Nakanishi, J. Ferment. Technol. 56, 573 (1978). Prepn of the aluminum complex: T. Kagawa et al., DE 2127176 corresp to US 3787466 (1971, 1974 both to Kyowa). Physico-chemical properties: E. Hayakawa et al., Yakugaku Zasshi 97, 731 (1977), C.A. 87, 141198 (1977). Effect on exptl chronic gastric ulcer: H. Tanaka et al., Oyo Yakuri 7, 1035 (1973), C.A. 81, 33283v (1974). Cytoprotective effect: H. Tanaka, Arzneim.-Forsch. 36, 1485 (1986).

Bismuth Butylthiolaurate CAS Registry Number: 53897-25-9

CAS Name: 2-(Butylthio)dodecanoic acid bismuth basic salt
Trademarks: Bispecia; Neocardyl
Percent Composition: C 36.23%, H 6.27%, Bi 39.39%, O 12.06%, S 6.04%
Literature References: Prepn: P. Lebeau, M. M. Janot, Traité Pharm. Chim. Vol. II (Masson, Paris, 4th ed., 1955-1956) p 435.

Pentagastrin CAS Registry Number: 5534-95-2 五肽胃泌素

CAS Name: N-[(1,1-Dimethylethoxy)carbonyl]-b-alanyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
Additional Names: N-carboxy-b-alanyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-al...
Literature References: Prepn: P. M. Hardy et al., BE 665591; eidem, US 3896103 (1965, 1975 to I.C.I.); Davey et al., J. Chem. Soc. C 1966, 555; Sakakibara et al., Bull. Chem. Soc. Jpn. 41, 438 (1968). Structure-function relationship studies: Morley et al., Nature 207, 1356 (1965). Formulation and pharmacological studies: Wai et al., J. Pharm. Pharmacol. 22, 923 (1970). Reviews: Makhlouf, Fed. Proc. 27, 1322 (1968); Sanders, Schimmel, Am. J. Med. 49, 380 (1970).